Neonatal management and outcome in alloimmune hemolytic disease

Ree, I.M.C.; Smits-Wintjens, V.E.H.J.; Bom, J.G. van der; Klink, J.M.M. van; Oepkes, D.; Lopriore, E.

Note: To cite this publication please use the final published version (if applicable).

Neonatal management and outcome in alloimmune hemolytic disease

Isabelle M. C. Ree, Vivianne E. H. J. Smits-Wintjens, Johanna G. van der Bom, Jeanine M. M. van Klink, Dick Oepkes & Enrico Lopriore

Accepted author version posted online: 13 May 2017.
Published online: 05 Jun 2017.

Submit your article to this journal ⬚

Article views: 9640

View related articles ⬚

View Crossmark data ⬚

Citing articles: 13 View citing articles ⬚

Taylor & Francis
Taylor & Francis Group

REVIEW

OPEN ACCESS
Check for updates

Neonatal management and outcome in alloimmune hemolytic disease

Isabelle M. C. Ree[a,b], Vivianne E. H. J. Smits-Wintjens[a], Johanna G. van der Bom[b], Jeanine M. M. van Klink[a], Dick Oepkes[c] and Enrico Lopriore[a]

[a]Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands; [b]Sanquin Blood Supply, Clinical Transfusion Research, Leiden, Zuid-Holland, The Netherlands; [c]Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands

ABSTRACT

Introduction: Hemolytic disease of the fetus and newborn (HDFN) occurs when fetal and neonatal erythroid cells are destroyed by maternal erythrocyte alloantibodies, it leads to anemia and hydrops in the fetus, and hyperbilirubinemia and kernicterus in the newborn. Postnatal care consists of intensive phototherapy and exchange transfusions to treat severe hyperbilirubinemia and top-up transfusions to treat early and late anemia. Other postnatal complications have been reported such as thrombocytopenia, iron overload and cholestasis requiring specific management.

Areas covered: This review focusses on the current neonatal management and outcome of hemolytic disease and discusses postnatal treatment options as well as literature on long-term neurodevelopmental outcome.

Expert commentary: Despite major advances in neonatal management, multiple issues have to be addressed to optimize postnatal management and completely eradicate kernicterus. Except for strict adherence to guidelines, improvement could be achieved by clarifying the epidemiology and pathophysiology of HDFN. Several pharmacotherapeutic agents should be further researched as alternative treatment options in hyperbilirubinemia, including immunoglobulins, albumin, phenobarbital, metalloporphyrins, zinc, clofibrate and prebiotics. Larger trials are warranted to evaluate EPO, folate and vitamin E in neonates. Long-term follow-up studies are needed in HDFN, especially on thrombocytopenia, iron overload and cholestasis.

1. Introduction

Hemolytic disease of the fetus and newborn (HDFN) is a condition in which fetal and neonatal erythroid cells are destroyed by maternal erythrocyte IgG alloantibodies that are transported across the placenta [1,2]. Maternal alloimmunization can be triggered by more than 50 different erythrocyte antigens, but most severe cases involve the Rhesus-D antigen (RhD), which causes Rhesus-mediated hemolytic disease [3]. The effects of the incompatibility of maternal and fetal erythrocytes range from anemia and hydrops in the fetus to hyperbilirubinemia and kernicterus in the newborn [2]. Management of HDFN is therefore a two-way effort, concerning both antenatal as well as postnatal strategies.

The most successful step in antenatal care of HDFN was the introduction of RhD immunoprophylaxis in 1968 [4]. Before immunoprophylaxis became available, HDFN affected 1% of all newborns worldwide and the mortality rate in affected fetuses was up to 50% [4]. The incidence of Rhesus hemolytic disease is now approximately 0.5% in RhD-negative women in industrialized countries [2,4]. However, despite adequate RhD immunoprophylaxis, 1–3 in 1000 RhD-negative women still develop anti-D antibodies [5]. Antenatal care not only involves immunoprophylaxis but also the monitoring of high-risk cases by laboratory testing and ultrasound-based techniques in order to detect fetal anemia. If necessary, severe fetal anemia is treated with intrauterine blood transfusions (IUTs) to prevent or treat fetal hydrops [6,7]. At least equally important in the management of HDFN is postnatal care. Postnatal care primarily involves the management and stabilization of the ill and frequently premature newborn [8] but revolves around the treatment of hyperbilirubinemia and prevention of kernicterus by intensive phototherapy and exchange transfusions. Except for hyperbilirubinemia, other postnatal complications of HDFN and their respective treatments have been reported and studied such as early and late anemia. To date, however, little attention has been devoted to complications such as thrombocytopenia, iron overload, and cholestasis. The long-term neurodevelopmental outcome has only recently been investigated in large cohorts. With the ongoing research on HDFN, it is important to highlight and summarize recent developments and to point out the remaining challenges for the future.

The antenatal treatment of HDFN will be discussed in detail in this journal in an upcoming review by Zwiers et al. This review focuses on the current postnatal management and outcome of HDFN. Recent literature is reviewed and discussed in a clinical point of view to assess current and future care of these infants. The main issues addressed in this paper are the various postnatal treatment options of hyperbilirubinemia and anemia, as well as long-term outcome.

2. Management of hyperbilirubinemia

In severe hyperbilirubinemia, unconjugated bilirubin can cross the blood–brain barrier and can potentially lead to bilirubin neurotoxicity. A condition defined as bilirubin-induced neurologic dysfunction (BIND) occurs, of which kernicterus or chronic bilirubin encephalopathy is known as its most severe and permanent clinical manifestation [9]. In the acute phase of BIND, symptoms include lethargy, hypotonia, and feeding problems. Untreated, hyperbilirubinemia can cause fever, a high-pitched cry, and hypertonia, eventually leading to apnea, coma, seizures, and death. In kernicterus, the most affected brain tissues are the basal ganglia, cerebellum, and various brainstem nuclei. Long-term morbidity in surviving infants includes athetoid cerebral palsy, hearing loss, and intellectual disability [10,11].

Standard care of hyperbilirubinemia consists of intensive phototherapy and, if indicated, exchange transfusions. Improvement of these treatments remains a constant and recurring focus of research, as well as the search for alternative treatments such as pharmacotherapeutic agents that might enhance treatment of hyperbilirubinemia in HDFN.

2.1. Intensive phototherapy

Since its introduction in the 1970s, phototherapy has been the main treatment for neonatal hyperbilirubinemia. Phototherapy causes photo isomerization of bilirubin in the skin to water-soluble isomers that can be excreted by the kidneys and stool without further metabolism by the liver. The efficacy of phototherapy depends on several factors, including the wavelength of the light used, the intensity of the light source, the total light dose (time under phototherapy and amount of skin exposed), and/or the threshold at which phototherapy is commenced [12-15]. The light used in phototherapy needs to penetrate the skin and be absorbed by bilirubin, which happens with blue or green light with an optimal wavelength range of 460–490 nm [12]. The intensity or irradiance (energy output) of the light source is measured with a radiometer in units of watts per square centimeter or in microwatts per square centimeter per nanometer over a given wavelength band [12]. Light-emitting diodes (LEDs) are the most commonly used phototherapy lamps, but also halogen lamps and fiberoptic systems such as biliblankets are used [10]. A recent systematic review by Woodgate et al. recommends close phototherapy (distance of 20 cm above the neonate) over distant light-source phototherapy (40 cm above the neonate) and double over single phototherapy, thus increasing the light irradiance. No clear benefit was found for continuous over intermittent phototherapy in neonates more than 2000 g or term infants, or for higher skin exposure by removing the diaper. Phototherapy should be applied once serum bilirubin levels reach predefined thresholds [15]. In HDFN, the use of intensive phototherapy is recommended. Intensive phototherapy is defined by the American Academy of Pediatrics (AAP) as a spectral irradiance of at least 30 µW per square centimeter per nanometer over the same bandwidth delivered to as much of the body-surface area as possible. In practice, intensive phototherapy is continuous with at least two lamps closely above the neonate and a biliblanket covering the whole body and back side of the neonate [10].

Phototherapy is generally considered a safe procedure and reports of significant toxicity are exceptionally rare and mostly limited to case reports [10,16]. Recently, two studies were published on a possible link between phototherapy and development of cancer. Specifically, the risk for myeloid leukemia and kidney cancer seemed slightly increased. However, after correcting for congenital and chromosomal abnormalities, the associations were no longer statistically significant [17,18]. Additionally, previous studies could not find an association between phototherapy and skin cancer [16,19]. Phototherapy does seem to be associated with the development of allergic diseases [20].

2.2. Fluid supplementation/hydration

Fluid supplementation during phototherapy may help the excretion of photoproducts through both urine and bile and to overcome the increased insensible water loss [21]. However, with the increased use of LED lights, the beneficial effect of fluid supplementation in neonates without dehydration becomes questionable, as LED lights have a much lower heat output and therefore less insensible water loss [12,14]. Intravenous fluid support has no effect on the rate of decrease in serum bilirubin and decrease in duration of phototherapy in healthy term newborns with no dehydration [22,23].

2.3. Exchange transfusion

In the 1940s, treatment of neonatal hyperbilirubinemia with exchange transfusions was introduced, initially as specific treatment for Rhesus hemolytic disease [24]. Exchange transfusions lower the serum bilirubin level and remove the antibody-coated neonatal erythrocytes and circulating maternal antibodies to reduce further erythrocyte destruction. Approximately 85% of the neonatal blood is replaced by irradiated donor blood double volume exchange transfusion, which has the additional benefit of providing new albumin with bilirubin binding sites and directly treating anemia [25,26]. However, exchange transfusions are not without risk. Current mortality rates are less than 0.3% in term neonates but increase above 10% in preterm neonates [27,28]. Morbidity rates are still high (up to 24%), even in term neonates, and include cardio-respiratory instability, apnea, catheter-related complications, thrombocytopenia, and infections [27–29].

There is no clear benefit for the use of single volume exchange transfusion as opposed to double volume exchange transfusion; double volume exchange transfusions is current practice [30]. Two-stage exchange transfusions showed to be more efficient than one-stage exchange transfusions in term neonates in single-volume transfusions. In the two-stage procedure, a first exchange transfusion is given with a 3-h resting period (allowing for equilibrium of bilirubin to be established between the intravascular and extravascular compartments), followed by a second stage. Two-stage exchange transfusion significantly lowered rebound serum bilirubin and the need for repeated exchange transfusions. There was no difference in mortality and morbidity between the two groups [31].

The frequency of exchange transfusions varies widely between studies but overall sharply declined since its introduction due to the emergence of phototherapy, the development of RhD immunoprophylaxis and improved monitoring, and care for hyperbilirubinemia [28]. Exchange transfusions are now recommended if bilirubin levels remain above exchange transfusion thresholds despite intensive phototherapy, or if signs of acute bilirubin encephalopathy occur [10]. The rate of exchange transfusion in HDFN decreased to around 20% after these more restrictive guidelines were published by the AAP [10,32].

In our center, the exchange transfusion rate in HDFN dropped from approximately 70% before 2005 [33] to approximately 15% thereafter [32]. This reduction was due to the implementation of a more restrictive guideline for exchange transfusions in terms of bilirubin cutoff values, especially by introducing cutoff values for different risk groups, compared to the more liberal guideline used at our center before 2005.

2.4. Intravenous immunoglobulin

Some studies have shown a reduced need for exchange transfusions in HDFN with the use of intravenous immunoglobulins [34]. Immunoglobulins seem to block Fc receptors on macrophages, which reduces the breakdown of antibody coated erythrocytes and lowers the circulating unconjugated bilirubin levels [35]. Administration of intravenous immunoglobulin (0.5–1 g/kg) is currently recommended by the AAP if the total serum bilirubin is rising despite intensive phototherapy or the bilirubin level is within 2–3 mg/dL (34–51 μmol/L) of the exchange level. If necessary, a repeated dose can be given in 12 h [10,34].

Despite current recommendations, a recent randomized controlled trial by Santos et al. and a recent randomized controlled trial in our center by Smits-Wintjens et al. could not support the efficacy of intravenous immunoglobulins in HDFN [23,36]. As efficacy is questioned, it is important to point out that although intravenous immunoglobulins are considered a safe treatment, rare but serious side effects have been reported, including transfusion transmitted diseases, anaphylaxis, hypersensitivity, thrombosis, pulmonary emboli, and renal failure [37]. A possible association with necrotizing enterocolitis (NEC) was found in a retrospective study comparing near-term infants with Rhesus hemolytic disease treated with immunoglobulins with a control group without immunoglobulin treatment [38]. In a meta-analysis by Yang et al., immunoglobulins showed an increased risk for NEC (OR 4.53; 95% CI, 2.34–8.79; $p < 0.001$), but not for final mortality [39]. A recent systematic review advocates further well-designed studies before conclusive advice can be given about the treatment of HDFN with intravenous immunoglobulins [40].

2.5. Alternatives

Several pharmacotherapeutic agents have been studied as possible treatment options in neonatal hyperbilirubinemia. The main focus is on albumin, phenobarbital, metalloporphyrins, zinc, clofibrate, and prebiotics. None of these agents is currently recommended as standard care in hyperbilirubinemia [10].

2.5.1. Albumin

As albumin binds bilirubin, it is thought that extra administered albumin can lower serum bilirubin levels. However, sufficiently powered trials on the clinical benefits are lacking and albumin administration is not recommended as standard care at this moment [10]. A small randomized controlled trial in India by Shahian et al. showed evidence that albumin administration prior to exchange transfusion is beneficial to lower total serum bilirubin levels post exchange and lower the mean duration of phototherapy [41]. A subsequent randomized controlled trial did not show the same effects [42]. The AAP marks it as an option to measure the serum albumin level in neonates with hyperbilirubinemia and to consider an albumin level below 3.0 g/dL as an extra risk factor to lower the phototherapy threshold. Furthermore, if an exchange transfusion is being considered, the serum albumin level should always be measured and with the bilirubin/albumin ratio used in determining the need for exchange transfusions. Albumin supplementation is not recommended [10].

2.5.2. Phenobarbital

Phenobarbital was used in an attempt to increase biliary flow in the 1970s. Phenobarbital increases hepatic uridine diphosphate (UDP)-glucuronosyl transferase (UGT) activity and the conjugation of bilirubin and has a possible positive effect on hepatic uptake of bilirubin [43,44]. A recent randomized clinical trial by Kaabneh et al. in neonates with HDFN showed a minor advantage of adding phenobarbital to phototherapy treatment [45]. However, phenobarbital acts slowly and is therefore not the treatment of choice when adequate phototherapy and exchange transfusions are available. There might be a role for antenatal maternal administration of phenobarbital, as positive results (decreased need for exchange transfusions) were found in a retrospective study by Trevett et al., although these results are yet to be confirmed [46].

2.5.3. Metalloporphyrins

Metalloporphyrins inhibit heme-oxygenase, the rate-limiting enzyme in the catabolism of heme to bilirubin. In this manner, metalloporphyrins decreases the production of bilirubin, rather than increasing the excretion of bilirubin [47]. Treatment with metalloporphyrins may reduce neonatal bilirubin levels and decrease the need for phototherapy and hospitalization. Sufficient evidence is lacking however to recommend routine treatment of hyperbilirubinemia with metalloporphyrins [48].

2.5.4. Zinc

Oral zinc is thought to reduce the serum bilirubin by decreasing the enterohepatic circulation of bilirubin [49]. However, recent systematic reviews by Mishra et al. and Sharma et al. concluded that there is currently no role for zinc in the treatment of neonatal hyperbilirubinemia. There seems to be no effect on duration of phototherapy, incidence of phototherapy, or age of starting of phototherapy [50,51].

2.5.5. Clofibrate

Clofibrate induces glucuronosyl transferase that changes bilirubin in a water-soluble form that can be excreted. It seems that clofibrate in combination with phototherapy lowers the level of bilirubin and shortens the duration of phototherapy in term neonates [52,53], but larger trials are needed to evaluate its effect. Further research is especially needed in hemolytic-caused hyperbilirubinemia, as these neonates were excluded in some of the trials [54].

2.5.6. Prebiotic supplementation

Recently, the role of prebiotic supplementation was focus for research on the treatment of neonatal hyperbilirubinemia. Prebiotics are thought to increase gastrointestinal motility and stool frequency, decrease viscosity of stool and the enterohepatic circulation of bilirubin, and improve feeding tolerance and growth of beneficial bacteria in the gut. Results seem promising in both preterm and term neonates with hyperbilirubinemia on total serum bilirubin levels as well as duration of phototherapy [55,56].

2.5.7. Antenatal corticosteroids

Antenatal treatment with corticosteroids has been shown to accelerate lung maturation in preterm infants and reduce the risks of respiratory disorders, especially in those born before 34-week gestation [57]. Although antenatal betamethasone given after 34-week gestation does not appear to decrease the risk of respiratory disorders, recent studies reveal that betamethasone reduces the risk of neonatal jaundice requiring phototherapy, possibly because of acceleration of liver maturation [58]. A randomized controlled trial comparing antenatal steroids to conventional treatment will be carried out in our center in the near future.

3. Management of anemia

Hemolysis of the fetal erythrocytes by maternal alloantibodies causes anemia. These alloantibodies remain in the neonatal circulation after birth for several months and can cause prolonged anemia. Anemia in hemolytic disease is divided in early anemia (onset at birth up to 7 days of age) and late anemia. Late anemia occurs in 83% of neonates of a gestational age of 35 weeks or more with HDFN and is further split into 'late hyporegenerative anemia' and 'late anemia of hemolytic disease' [59]. Late hyporegenerative anemia is caused by depressed erythropoiesis and is characterized subsequently by low reticulocyte counts. Underlying mechanisms are proposed to be the following: intramedullary destruction of erythrocyte precursors, bone marrow suppression from intrauterine and postnatal transfusions, erythropoietin (EPO) deficiency; shortened half-life of transfused erythrocytes, and relative anemia due to the expanding intravascular volume of the growing neonate. Late anemia of hemolytic disease is characterized by age-appropriate or elevated reticulocyte counts, reflecting an active bone marrow to compensate for the shortened erythrocyte survival. This form of late anemia is thought to be due to a combination of continuing hemolysis by remaining antibodies, shortened survival of transfused erythrocytes, natural decline of the hemoglobin level, and the expanding intravascular volume of the growing neonate [59,60].

Interestingly, although late anemia was already described before IUTs were available, IUTs seem to actually increase the risk of postnatal anemia. The pathophysiological mechanism is not entirely understood, but treatment with repeated IUTs possibly lead to persistent anemia due to suppression of erythropoiesis [33].

Primary treatment of anemia in HDFN is administering erythrocyte transfusions, known as top-up transfusions. In addition, several pharmacological agents are used to stimulate erythropoiesis.

3.1. Top-up transfusions

Late anemia usually resolves by the third month of life; until then, erythrocyte transfusions may be necessary to treat postpartum anemia [59,61]. The mean postnatal age for a first top-up transfusion in HDFN is 18 days (range 1–34) [62]. At least one top-up transfusion is reported to be required in 68–83% of neonates with HDFN [33,59,63]. Some neonates need up to six top-up transfusions in the first 3 months of life [62]. In neonates that were treated with IUTs, the top-up transfusion rate is significantly higher (77–89%), than in neonates that were not treated with IUTs (27–67%) [33,59,63]. In the IUT group, the median number of top-up transfusions was 1 (range, 0–4), compared to 0 (range, 0–2) in non-IUT group ($p < 0.01$) [33]. This difference can be explained by a depressed erythropoiesis and is correlated with a significantly lower reticulocyte count at birth in transfused neonates [33,62,64].

Variations in the percentage of neonates requiring top-up transfusions may be explained by various factors, including differences in transfusion guidelines and thresholds for erythrocyte transfusions. In our center, a top-up transfusion of 15 mL/kg irradiated erythrocytes is indicated in term neonates with HDFN when hemoglobin levels fall below 7.2 g/dL (4.5 mmol/L) or below 8.8 g/dL (5.5 mmol/L) when clinical symptoms of anemia are present (increased oxygen need, poor feeding, tachycardia, and/or tachypnea).

3.2. Exchange transfusion

Exchange transfusions not only have a positive effect on the clearance of bilirubinemia in hemolytic disease, but as mentioned before, but it also treats anemia as the neonatal blood is replaced by immunologically compatible donor blood and decreases plasma ferritin and iron levels [25]. The reduced need for exchange transfusion in the last decades seems to be associated with an increased need for top-up transfusions. This is probably explained by longer lasting hemolysis due to a reduced clearance of maternal antibodies [33,63].

3.3. Delayed cord clamping

Delayed cord clamping at birth allows additional placental blood transfusion. In a term newborn, this transfusion can consist up to one-quarter to one-third of the total neonatal blood volume [65]. In anemia secondary to erythrocyte

alloimmunization, a significant increase in hemoglobulin levels at birth was observed, as well as a longer delay between birth and first transfusion, and a decrease in the number of postnatal exchange transfusions, with no notable adverse effects [66,67].

3.4. Pharmacotherapeutic options

In erythropoiesis, sufficient amounts of EPO, folate, iron, and vitamin E are essential. To enhance erythropoiesis, administration of these nutrients may have a beneficial effect in the treatment of anemia in HDFN [68,69].

3.4.1. EPO
EPO is the principle growth factor responsible for fetal and neonatal erythropoiesis and is primarily developed in the fetal liver [70], since over a decade, recombinant human EPO has been applied in small studies and casuistic reports, with different outcomes for the occurrence of anemia and the need for top-up transfusions in neonates with HDFN [71–74]. Due to limited clinical importance of observed beneficial effects, routine use of EPO is currently not recommended [75]. A well-designed randomized controlled clinical trial of sufficient sample size is required to establish the role of EPO in the treatment of HDFN [69] and will be carried out in our center in the near future. In this trial, included neonates will be randomized at birth to treatment with darbepoetin or conventional care. The intervention group will receive darbepoetin subcutaneously once a week in 10 U/kg/dose for 8 weeks.

3.4.2. Folate
Folate plays a role in the proliferation of erythroblasts during their differentiation [68]. Very limited data are available on its therapeutic efficacy, although a small effect has been seen in the addition of both vitamin B12 (3 μg/kg/day) and folate (100 μg/kg/day) to EPO as treatment in anemia of prematurity [76]. Due to the prolonged anemia often seen in HDFN, folate is supplemented in our center for 3 months postpartum in a dosage of 250 μg/day.

3.4.3. Iron
Iron is required for hemoglobin synthesis by erythroblasts. The use of iron in anemia associated with HDFN has been studied most extensively in combination with EPO. Administration of EPO without, or with, low iron supplementation can lead to iron deficiency and ineffective erythropoiesis [69,77]. However, neonates with HDFN tend to have an iron overload due to the combination of prolonged hemolysis and treatment with multiple IUTs and erythrocyte transfusions. Based on current knowledge, iron supplementation should be withheld, especially in transfused infants as it is associated with numerous potential adverse effects [78,79].

3.4.4. Vitamin E
It is unclear whether vitamin E acts as an antioxidant that protects the erythrocyte membrane or as an erythropoietic factor, but shortage of vitamin E might be an additional cause of anemia [80]. Limited data are available on the therapeutic effects of vitamin E. A pilot study of Pathak et al. showed that oral supplementation at 50 IU/day does not enhance the response of preterm neonates to EPO and iron, compared to placebo [81].

4. Management of other complications

4.1. BIND and kernicterus

Although rare, BIND and kernicterus are still occurring in the industrialized world. According to rough estimates based on national registration systems, a severely high bilirubin count (>420 μmol/l) occurs in 100–200 infants a year in the Netherlands (i.e. 0.5–1 per 1000 live births). Although cases of kernicterus are reported several times a year, precise estimates on the prevalence of kernicterus are not available [82]. Alarmingly, throughout the 1990s, a significant rise in case reports of kernicterus occurred compared to previous years. This rise was attributed to a combination of reduced concern for jaundice in newborns, early discharge with inadequate follow-up and a decreased awareness of the long-term complications of hyperbilirubinemia and guidelines were updated and implemented accordingly [83]. Cornerstone of the management of BIND and kernicterus is timely and adequate treatment of hyperbilirubinemia. Rather than applying phototherapy and exchange transfusions when necessary, the treatment of hyperbilirubinemia is a complex interplay of adequate screening of at-risk pregnancies, anticipation of the hyperbilirubinemic neonate, and the combination of antenatal and postnatal management. The importance of this interplay is also reflected in the nonlinear relationship between neonatal bilirubin levels and the risk of BIND and kernicterus and the wide variety of clinical manifestations, varying between neurodevelopmental difficulties (including developmental delay, cognitive impairment, and disordered executive function), and behavioral and psychiatric disorders [84].

4.2. Thrombocytopenia

In severe HDFN, thrombocytopenia is believed to be caused by increased erythropoiesis as it can suppress the other cell lines and potentially cause leucopenia and thrombocytopenia [85]. A retrospective study in our center showed a 26% incidence of thrombocytopenia (platelet count <150 × 10^9/L) in neonates treated with IUT for Rhesus D hemolytic disease. The occurrence of thrombocytopenia was an independent risk factor for perinatal mortality [86]. A more recent retrospective observational study was carried out in our center and also showed a similar incidence of 26% of thrombocytopenia in all neonates with HDFN at birth. Severe thrombocytopenia was found in 6% of neonates. Three risk factors were independently associated with thrombocytopenia at birth: treatment with IUT, being born 'small-for-gestational-age' (defined as a birth weight below the 10th percentile) and lower gestational age at birth [87]. Thrombocytopenia in HDFN is usually a self-limiting disease but treatment with platelet transfusions may be needed if platelets drop below transfusion threshold.

4.3. Iron overload

As mentioned before, neonates with Rhesus hemolytic disease tend to have an iron overload. This is caused by the combination of prolonged hemolysis and treatment with multiple IUTs and erythrocyte transfusions [72,73,88]. Although iron is essential in early brain development and function, iron overload can have detrimental health effects as well. It causes damage to the liver, heart, and endocrine organs, alters immune response, and increases susceptibility to infection [89]. Iron deficiency in the first 3 months of life is very rare in HDFN and has not been described in neonates that received postnatal top-up transfusions. Iron overload occurs in 70% of neonates with HDFN at birth, 50% at the age of 1 month and 18% at the age of 3 months. In neonates with HDFN that received IUTs, ferritin levels were twice as high compared to controls at birth (mean 598 ± 249 vs. 270 ± 111 µg/L, $p < 0.001$) [73]. The use of iron supplementation in the first 3 months of life in neonates with severe HDFN is strongly discouraged, particularly after IUTs.

4.4. Cholestasis

Conjugated hyperbilirubinemia (cholestasis) has been described in neonates with HDFN [90,91] and can give rise to suspicion of underlying liver disease with additional diagnostic measures. A retrospective study in our center showed a total incidence of cholestasis in infants with RHDN of 13% (41/313). Cholestasis in hemolysis might be caused by obstruction of the excretory system by excessive conjugated bilirubin and should primarily be regarded as complication of HDFN. Treatment with one or more IUT and RhD alloimmunization were independent risk factors for cholestasis. Cholestasis resolved spontaneously within 1 week–3 months after birth in almost half of the patients, but the authors advocate larger studies to confirm these findings and to determine the exact course and etiology of cholestasis in HDFN [92].

5. Long-term outcome

With the improvements in antenatal and neonatal management over the past decades, survival has significantly improved in HDFN. As mortality rates are lower, attention is shifting toward the long-term outcome in the surviving neonates. Adverse prenatal conditions including impaired fetal nutrition and growth can have a profound and long-lasting impact on physical and mental health throughout life, for example increased risk of cardiovascular disease, neuropsychological disorders, and metabolic disease [93,94]. The impact of severe fetal and neonatal anemia, hyperbilirubinemia and of the (invasive) procedures and treatments fetuses and neonates with HDFN are exposed to is unknown but seem to justify long-term follow-up studies as current data are limited [95].

5.1. Long-term outcome after IUT

A large long-term follow-up study in our center, the LOTUS study (Long-Term follow-up after intra-Uterine transfusionS), was performed to determine the incidence of neurodevelopmental impairment (NDI) in children treated with IUT for HDFN (between 1988 and 2008). A total of 291 children were studied at a median age of 8.2 years. NDI was defined as the presence of one or more of the following: cerebral palsy, severe developmental delay, bilateral blindness, and/or deafness. The incidence of severe NDI was 3.1%, comparable to the Dutch normative population (2.3%). The overall rate of NDI was 4.8% (14/291). In a multivariate regression analysis, the number of IUTs, severe neonatal morbidity, parental education, and severe prenatal hydrops were independent risk factors associated with NDI [96].

Health-related quality of life and behavioral functioning in 285 children and adolescents treated with IUT for alloimmune anemia was recently assessed at our center [97]. Parents reported lower scores on cognitive functioning in their children aged 6–11 years compared to Dutch norms. Behavioral difficulties were more prevalent than norms and associated with maternal educational level. Overall, in the majority of survivors, long-term outcome following IUT for alloimmune anemia appears favorable.

Hypothetically, the chronic anemia caused by immune hemolysis in the fetus results in the need for increased cardiac output and may lead to myocardial hypertrophy. Limited data show that HDFN treated with IUT may lead to less myocardial mass in childhood, but the long-term cardiovascular consequences in adult life are unknown [95]. However, very recently, a retrospective cohort study by Wallace et al. was published on the cardiac function and cardiovascular risk factors in adults exposed to fetal anemia and intrauterine transfusion ($n = 95$), compared to their healthy siblings. The former patients showed smaller left ventricular volumes, increased left ventricular wall thickness, and decreased myocardial perfusion at rest, concluding that cardiovascular development is altered after exposure to fetal anemia and IUT. It is unknown whether this will have clinical consequences regarding the development of cardiovascular disease as the average age at the time of study was 34 years [98].

5.2. Long-term outcome after immunoglobulins

In a follow-up study of a randomized controlled trial conducted at our center, we found that the neurodevelopmental outcome in children treated with intravenous immunoglobulins for HDFN was not different from children treated with placebo [32,99]. At a median age of 4 years, NDI was detected in 3% in both the IVIG (1/34) and placebo (1/32) group. After stratification for treatment with or without IUT, similar results were obtained. Standardized long-term follow-up studies with large enough case series and sufficient power are needed to replicate these findings.

6. Conclusion

Over the years, neonatal management and outcome in HDFN improved significantly. Classical therapies such as intensive phototherapy and exchange transfusions for hyperbilirubinemia and erythrocyte transfusions for anemia are well studied but are still improved upon. Alternative treatments have been suggested such as albumin, phenobarbital, metalloporphyrins, zinc, clofibrate, and prebiotics in hyperbilirubinemia and EPO,

folate, iron, and vitamin E in anemia. These alternative agents have varyingly been studied but lack evidence to support their use. Although long-term outcome in HDFN seems favorable, neonates with fetal hydrops have a general bad outcome. This emphasizes the need for adequate screening and treatment, preferably regulated by nationwide guidelines and monitoring.

7. Expert commentary

Our clinical experience, as a tertiary referral center of Neonatology, is in line with the conclusions reported above. The Leiden University Medical Center is the national referral center for HDFN in the Netherlands, which allowed us to develop as an expertise center and to play an important role nationwide in the care for these neonates. Despite major advances in the field of HDFN, multiple issues still need to be addressed in the future to optimize the postnatal management of neonates with HDFN.

First, it is important to emphasize that major improvements could probably be achieved by strict adherence to guidelines. Clear guidelines on screening and management appear to have significant effect but have to be evaluated continuously and implemented around the globe. Strict adherence to guidelines is recommended to further eradicate kernicterus and treat affected fetuses and neonates effectively.

Second, to further assess the extent of the problems in the management of HDFN, it is important to assess its epidemiologic aspect. We need exact and national numbers on the occurrence of hyperbilirubinemia, exchange transfusions and kernicterus as well as insight in clinical course and pitfalls in these cases. To better asses these cases, the pathophysiologic mechanisms also have to be better understood. For example, not much is known on BIND and why some infants develop kernicterus and others with an equally high serum bilirubin do not. It is also unclear what the exact mechanism of late anemia is and why some neonates require top-up transfusions up to 3 months of life.

Third, pharmacotherapeutic agents should be further researched as potential alternatives for and supplements to classical treatments. As pointed out, the role of albumin supplementation (prior to exchange transfusion), phenobarbital (especially antenatal maternal administration), metalloporphyrins, zinc, clofibrate, and prebiotics in hyperbilirubinemia needs to be clarified. Prospective, double-blinded RCTs are necessary to evaluate outcome and adverse effects, ideally in HDFN-specific patient groups. The use of immunoglobulins in Rhesus haemolytic disease should be re-evaluated on efficacy and safety in the prevention of exchange transfusions. Larger trials are warranted to evaluate the use of EPO, folate, and vitamin E in neonates with HDFN in the treatment of postnatal anemia. Due to the low occurrence rate of HDFN, these trials should be multicenter international studies to reach sufficient power.

Lastly, there is a general lack of long-term follow-up studies in HDFN. Especially, complications such as thrombocytopenia, iron overload, and cholestasis should be studied in terms of short-term and long-term effects.

The ultimate goal in HDFN is timely detection and treatment of maternal alloimmunization in an effort to lower the occurrence of hyperbilirubinemia and to completely eradicate kernicterus, with a prosperous long-term prognosis for all affected neonates.

8. Five-year view

Detection and management of HDFN have vastly improved in the last decades. Unfortunately, it is still a major cause of hyperbilirubinemia and, on occasion, kernicterus. The eradication of kernicterus has been a worldwide point of interest and can partly be achieved by adequate management of neonates with HDFN. By strict compliance to national guidelines, HDFN can be timely recognized and treated. It would be desirable in the future to obtain more information of the associations between serum bilirubin levels and neurologic damage, as well as epidemiologic information. Much attention is currently focused at identifying new pharmacological agents in HDFN. Some of these have already been used in clinical practice; others are currently under evaluation or await proper designed trials. Studies are needed on the impact of treatment in the long-term follow-up.

Key issues

- Despite RhD immunoprophylaxis, 1 to 3 in 1000 RhD negative woman develop anti-D antibodies, therefore HDFN is still a relevant condition of which treatment needs to be optimized.
- Guidelines for hyperbilirubinemia and specifically for this group should be implemented worldwide and strictly followed.
- Intensive phototherapy and exchange transfusions are the treatment of choice in hemolytic hyperbilirubinemia, although alternative pharmacotherapeutic agents are researched.
- Late anemia is a common problem in neonates with HDFN and can last up to three months of age. In Rhesus hemolytic disease the majority of neonates needs at least one to up to six top-up transfusions.
- HDFN is associated with postnatal thrombocytopenia, iron overload and cholestasis.
- Limited studies are available on long-term outcome in HDFN, but generally show a favorable outcome in neonates that did not develop kernicterus.

Declaration of interest

References

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

1. de Haas M, Thurik FF, Koelewijn JM, et al. Haemolytic disease of the fetus and newborn. Vox Sang. 2015;109:99–113.
2. Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev. 2000;14:44–61.
3. Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med. 2008;13:207–214.
4. Bowman J. Thirty-five years of Rh prophylaxis. Transfusion. 2003;43:1661–1666.
5. Koelewijn JM, de Haas M, Vrijkotte TGM, et al. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion. 2008;48:1721–1729.
6. Bennardello F, Coluzzi S, Curciarello G, et al. Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn. Blood Transfus. 2015;13:109–134.
7. Illanes S, Soothill P. Management of red cell alloimmunisation in pregnancy: the non-invasive monitoring of the disease. Prenat Diagn. 2010;30:668–673.
8. Fan J, Lee BK, Wikman AT, et al. Associations of Rhesus and non-Rhesus maternal red blood cell alloimmunization with stillbirth and preterm birth. Int J Epidemiol. 2014;43:1123–1131.
9. Bhutani VK, Johnson-Hamerman L. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Fetal Neonatal Med. 2015;20:6–13.
10. American Academy of Pediatrics Subcommittee on H. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114:297–316.
11. Shapiro SM, Bhutani VK, Johnson L. Hyperbilirubinemia and kernicterus. Clin Perinatol. 2006;33:387–410.
12. Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. New Engl J Med. 2008;358:920–928.
13. Stokowski LA. Fundamentals of phototherapy for neonatal jaundice. Adv Neonatal Care. 2011;11:S10–S21.
14. Vreman HJ, Wong RJ, Stevenson DK. Phototherapy: current methods and future directions. Semin Perinatol. 2004;28:326–333.
15. Woodgate P, Jardine LA. Neonatal jaundice: phototherapy. BMJ Clin Evid. 2015;2015:0319.
16. Xiong T, Qu Y, Cambier S, et al. The side effects of phototherapy for neonatal jaundice: what do we know? What should we do? Eur J Pediatr. 2011;170:1247–1255.
17. Newman TB, Wickremasinghe AC, Walsh EM, et al. Retrospective cohort study of phototherapy and childhood cancer in northern California. Pediatrics. 2016;137:e20151354.
18. Wickremasinghe AC, Kuzniewicz MW, Grimes BA, et al. Neonatal phototherapy and infantile cancer. Pediatrics. 2016;137:e20151353.
19. Lai YC, Yew YW. Neonatal blue light phototherapy and melanocytic nevus count in children: a systematic review and meta-analysis of observational studies. Pediatr Dermatol. 2016;33:62–68.
20. Das RR, Naik SS. Neonatal hyperbilirubinemia and childhood allergic diseases: a systematic review. Pediatr Allergy Immunol. 2015;26:2–11.
21. Maayan-Metzger A, Yosipovitch G, Hadad E, et al. Transepidermal water loss and skin hydration in preterm infants during phototherapy. Am J Perinatol. 2001;18:393–396.
22. Boo N-Y, Lee H-T. Randomized controlled trial of oral versus intravenous fluid supplementation on serum bilirubin level during phototherapy of term infants with severe hyperbilirubinaemia. J Paediatr Child Health. 2002;38:151–155.
23. Mehta S, Kumar P, Narang A. A randomized controlled trial of fluid supplementation in term neonates with severe hyperbilirubinemia. J Pediatr. 2005;147:781–785.
24. Diamond LK, Allen FH Jr., Thomas WO Jr. Erythroblastosis fetalis. VII. Treatment with exchange transfusion. N Engl J Med. 1951;244:39–49.
25. Murki S, Kumar P. Blood exchange transfusion for infants with severe neonatal hyperbilirubinemia. Semin Perinatol. 2011;35:175–184.
26. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med. 2001;344:581–590.
27. Chitty HE, Ziegler N, Savoia H, et al. Neonatal exchange transfusions in the 21st century: a single hospital study. J Paediatr Child Health. 2013;49:825–832.
   • Recent series of a single-center experience on the risks associated with exchange transfusions.
28. Steiner LA, Bizzarro MJ, Ehrenkranz RA, et al. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics. 2007;120:27–32.
29. Patra K, Storfer-Isser A, Siner B, et al. Adverse events associated with neonatal exchange transfusion in the 1990s. J Pediatr. 2004;144:626–631.
30. Abbas W, Attia NI, Hassanein SMA. Two-stage single-volume exchange transfusion in severe hemolytic disease of the newborn. J Matern Fetal Neonatal Med. 2012;25:1080–1083.
31. Thayyil S, Milligan DW. Single versus double volume exchange transfusion in jaundiced newborn infants. Cochrane Database Syst Rev. 2006;4:CD004592.
32. Smits-Wintjens VEHJ, Walther FJ, Rath MEA, et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics. 2011;127:680–686.
   •• RCT with low risk of bias showing the absence of benefit of IVIG in neonates with Rhesus disease.
33. de Boer IP, Zeestraten ECM, Lopriore E, et al. Pediatric outcome in Rhesus hemolytic disease treated with and without intrauterine transfusion. Am J Obstet Gynecol. 2008;198(1):54.e1–54.e4.
34. Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2003;88:F6–F10.
35. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011;127:315–323; quiz 24–25.
36. Santos MC, Sá C, Gomes SC Jr., et al. The efficacy of the use of intravenous human immunoglobulin in Brazilian newborns with rhesus hemolytic disease: a randomized double-blind trial. Transfusion. 2013;53:777–782.
   •• RCT with low risk of bias showing the absence of benefit of IVIG in neonates with Rhesus disease.
37. Walsh S, Molloy EJ. Towards evidence based medicine for paediatricians. Is intravenous immunoglobulin superior to exchange transfusion in the management of hyperbilirubinaemia in term neonates? Arch Dis Child. 2009;94:739–741.
38. Figueras-Aloy J, Rodríguez-Miguélez JM, Iriondo-Sanz M, et al. Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics. 2010;125:139–144.
39. Yang Y, Pan -J-J, Zhou X-G, et al. The effect of immunoglobulin treatment for hemolysis on the incidence of necrotizing enterocolitis - a meta-analysis. Eur Rev Med Pharmacol Sci. 2016;20:3902–3910.
40. Louis D, More K, Oberoi S, et al. Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2014;99:F325–F331.
41. Shahian M, Moslehi MA. Effect of albumin administration prior to exchange transfusion in term neonates with hyperbilirubinemia–a randomized controlled trial. Indian Pediatr. 2010;47:241–244.
42. Dash N, Kumar P, Sundaram V, et al. Pre exchange albumin administration in neonates with hyperbilirubinemia: a randomized controlled trial. Indian Pediatr. 2015;52:763–767.
43. Kaplan M, Wong RJ, Sibley E. Neonatal-perinatal medicine. 9th ed. Cleveland (OH): Mosby; 2011.
44. Yaffe SJ, Levy G, Matsuzawa T, et al. Enhancement of glucuronide-conjugating capacity in a hyperbilirubinemic infant due to apparent enzyme induction by phenobarbital. N Engl J Med. 1966;275:1461–1466.
45. Kaabneh MA, Salama GS, Shakkoury AG, et al. Phenobarbital and phototherapy combination enhances decline of total serum bilirubin and may decrease the need for blood exchange transfusion in

newborns with isoimmune hemolytic disease. Clin Med Insights Pediatr. 2015;9:67–72.

46. Trevett TN Jr., Dorman K, Lamvu G, et al. Antenatal maternal administration of phenobarbital for the prevention of exchange transfusion in neonates with hemolytic disease of the fetus and newborn. Am J Obstet Gynecol. 2005;192:478–482.

47. Stevenson DK, Rodgers PA, Vreman HJ. The use of metalloporphyrins for the chemoprevention of neonatal jaundice. Am J Dis Child. 1989;143:353–356.

48. Suresh GK, Martin CL, Soll RF. Metalloporphyrins for treatment of unconjugated hyperbilirubinemia in neonates. Cochrane Database Syst Rev. 2003;2:CD004207.

49. Méndez-Sánchez N, Roldán-Valadez E, Flores MA, et al. Zinc salts precipitate unconjugated bilirubin in vitro and inhibit enterohepatic cycling of bilirubin in hamsters. Eur J Clin Invest. 2001;31:773–780.

50. Mishra S, Cheema A, Agarwal R, et al. Oral zinc for the prevention of hyperbilirubinaemia in neonates. Cochrane Database Syst Rev. 2015;7:CD008432.

51. Sharma D, Farahbakhsh N, Sharma P, et al. Role of oral zinc supplementation for reduction of neonatal hyperbilirubinemia: a systematic review of current evidence. J Matern Fetal Neonatal Med. 2016;17:1–10.

52. Fallah R, Islami Z, Lotfi SR. Single dose of 50 mg/kg clofibrate in jaundice of healthy term neonates: randomised clinical trial of efficacy and safety. Indian J Pediatr. 2012;79:194–197.

53. Habibi M, Mahyar A, Ayazi P, et al. The effect of clofibrate on hyperbilirubinemia of term neonates. Acta Med Iran. 2012;50:21–25.

54. Gholitabar M, McGuire H, Rennie J, et al. Clofibrate in combination with phototherapy for unconjugated neonatal hyperbilirubinaemia. Cochrane Database Syst Rev. 2012;12:CD009017.

55. Armanian AM, Barekatain B, Hoseinzadeh M, et al. Prebiotics for the management of hyperbilirubinemia in preterm neonates. J Matern Fetal Neonatal Med. 2016;29:3009–3013.

56. Bisceglia M, Indrio F, Riezzo G, et al. The effect of prebiotics in the management of neonatal hyperbilirubinaemia. Acta Paediatr. 2009;98:1579–1581.

57. Gamsu HR, Mullinger BM, Donnai P, et al. Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. Br J Obstet Gynaecol. 1989;96:401–410.

58. Porto AM, Coutinho IC, Correia JB, et al. Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ. 2011;342:d1696.

59. Al-Alaiyan S, Al Omran A. Late hyporegenerative anemia in neonates with rhesus hemolytic disease. J Perinat Med. 1999;27:112–115.

60. Strand C, Polesky HF. Delayed anemia in erythroblastosis fetalis. Minn Med. 1972;55:439–441.

61. Smits-Wintjens VE, Walther FJ, Lopriore E. Rhesus haemolytic disease of the newborn: postnatal management, associated morbidity and long-term outcome. Semin Fetal Neonatal Med. 2008;13:265–271.

62. Rath ME, Smits-Wintjens VE, Lindenburg IT, et al. Exchange transfusions and top-up transfusions in neonates with Kell haemolytic disease compared to Rh D haemolytic disease. Vox Sang. 2011;100:312–316.

63. Rath ME, Smits-Wintjens VE, Lindenburg I, et al. Top-up transfusions in neonates with Rh hemolytic disease in relation to exchange transfusions. Vox Sang. 2010;99:65–70.

64. Millard DD, Gidding SS, Socol ML, et al. Effects of intravascular, intrauterine transfusion on prenatal and postnatal hemolysis and erythropoiesis in severe fetal isoimmunization. J Pediatr. 1990;117:447–454.

65. Farrar D, Airey R, Law GR, et al. Measuring placental transfusion for term births: weighing babies with cord intact. Bjog. 2011;118:70–75.

66. Garabedian C, Rakza T, Drumez E, et al. Benefits of delayed cord clamping in red blood cell alloimmunization. Pediatrics. 2016;137:e20153236.

67. McAdams RM. Delayed cord clamping in red blood cell alloimmunization: safe, effective, and free? Transl Pediatr. 2016;5:100–103.

68. Koury MJ, Ponka P. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr. 2004;24:105–131.

69. Mainie P. Is there a role for erythropoietin in neonatal medicine? Early Hum Dev. 2008;84:525–532.

70. Zanjani ED, Ascensao JL, McGlave PB, et al. Studies on the liver to kidney switch of erythropoietin production. J Clin Invest. 1981;67:1183–1188.

71. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006;3:CD004865.

72. Nicaise C, Gire C, Casha P, et al. Erythropoietin as treatment for late hyporegenerative anemia in neonates with Rh hemolytic disease after in utero exchange transfusion. Fetal Diagn Ther. 2002;17:22–24.

73. Pessler F, Hart D. Hyporegenerative anemia associated with Rh hemolytic disease: treatment failure of recombinant erythropoietin. J Pediatr Hematol Oncol. 2002;24:689–693.

74. Zuppa AA, Alighieri G, Calabrese V, et al. Recombinant human erythropoietin in the prevention of late anemia in intrauterine transfused neonates with Rh-isoimmunization. J Pediatr Hematol Oncol. 2010;32:e95–e101.
   • **Small study on the potential benefits of rhEPO in the prevention of late hyporegenerative anemia in neonates with Rhesus disease treated with IUT.**

75. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2014;4:CD004863.

76. Haiden N, Klebermass K, Cardona F, et al. A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity. Pediatrics. 2006;118:180–188.

77. Carnielli VP, Da Riol R, Montini G. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1998;79:F44–F48.

78. Berger HM, Lindeman JH, van Zoeren-Grobben D, et al. Iron overload, free radical damage, and rhesus haemolytic disease. Lancet. 1990;335:933–936.

79. Rath ME, Smits-Wintjens VE, Oepkes D, et al. Iron status in infants with alloimmune haemolytic disease in the first three months of life. Vox Sang. 2013;105:328–333.

80. Kling PJ, Schmidt RL, Roberts RA, et al. Serum erythropoietin levels during infancy: associations with erythropoiesis. J Pediatr. 1996;128:791–796.

81. Pathak A, Roth P, Piscitelli J, et al. Effects of vitamin E supplementation during erythropoietin treatment of the anaemia of prematurity. Arch Dis Child Fetal Neonatal Ed. 2003;88:F324–F328.

82. Bousema S, Govaert P, Dudink J, et al. [Kernicterus is preventable but still occurs]. Ned Tijdschr Geneeskd. 2015;159:A8518. Dutch.

83. Hansen TWR. Kernicterus: an international perspective. Semin Neonatol. 2002;7:103–109.

84. Wusthoff CJ, Loe IM. Impact of bilirubin-induced neurologic dysfunction on neurodevelopmental outcomes. Semin Fetal Neonatal Med. 2015;20:52–57.

85. Koenig JM, Christensen RD. Neutropenia and thrombocytopenia in infants with Rh hemolytic disease. J Pediatr. 1989;114:625–631.

86. van den Akker ESA, de Haan TR, Lopriore E, et al. Severe fetal thrombocytopenia in Rhesus D alloimmunized pregnancies. Am J Obstet Gynecol. 2008;199(4):387.e1–387.e4.

87. Rath ME, Smits-Wintjens VE, Oepkes D, et al. Thrombocytopenia at birth in neonates with red cell alloimmune haemolytic disease. Vox Sang. 2012;102:228–233.

88. Aygun C, Tekinalp G, Gurgey A. Increased fetal iron load in rhesus hemolytic disease. Pediatr Hematol Oncol. 2004;21:329–333.

89. Siddappa AM, Rao R, Long JD, et al. The assessment of newborn iron stores at birth: a review of the literature and standards for ferritin concentrations. Neonatology. 2007;92:73–82.

90. Allgood C, Bolisetty S. Severe conjugated hyperbilirubinaemia and neonatal haemolysis. Int J Clin Pract. 2006;60:1513–1514.

91. Dunn PM. Obstructive jaundice and haemolytic disease of the newborn. Arch Dis Child. 1963;38:54–61.

92. Smits-Wintjens VEHJ, Rath MEA, Lindenburg ITM, et al. Cholestasis in neonates with red cell alloimmune hemolytic disease: incidence, risk factors and outcome. Neonatology. 2012;101:306–310.

93. Barker DJ, Osmond C, Golding J, et al. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ. 1989;298:564–567.

94. Heijmans BT, Tobi EW, Stein AD, et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A. 2008;105:17046–17049.

95. Lindenburg ITM, van Klink JM, Smits-Wintjens VEHJ, et al. Long-term neurodevelopmental and cardiovascular outcome after intrauterine transfusions for fetal anaemia: a review. Prenat Diagn. 2013;33:815–822.

96. Lindenburg IT, Smits-Wintjens VE, van Klink JM, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol. 2012;206(2):141.e1–141.e8.

•• Largest follow-up study (*n* = 291) in Rhesus disease treated with intrauterine transfusion.

97. van Klink JMM, Lindenburg ITM, Inklaar MJ, et al. Health-related quality of life and behavioral functioning after intrauterine transfusion for alloimmune anemia. J Pediatr. 2015;167:1130-5.e2.

98. Wallace AH, Dalziel SR, Cowan BR, et al. Long-term cardiovascular outcome following fetal anaemia and intrauterine transfusion: a cohort study. Arch Dis Child. 2017;102(1):40–45.

99. van Klink JMM, van Veen SJ, Smits-Wintjens VEHJ, et al. Immunoglobulins in neonates with Rhesus hemolytic disease of the fetus and newborn: long-term outcome in a randomized trial. Fetal Diagn Ther. 2016;39:209–213.